Adequate nutrition is important for growth and meeting developmental milestones for all children. But for pediatric liver patients, overnutrition or undernutrition can have devastating effects.
Andrew P. Keaveny, MD, FRCPI, FAASLD
Consultant Hepatologist and Medical Director of Liver Transplant, Mayo Clinic, Jacksonville, Florida; Associate Professor of Medicine, Mayo Clinic College of Medicine and Science; Chair, AASLD Annual Meeting Education Committee; Member of the AASLD Maintenance of Certification and Scientific Planning Committees
The management of hepatocellular cancer (HCC) saw meaningful advances in 2016 with the introduction of two compounds, regorafenib and lenvatinib, for patients with advanced HCC.
Four experts will discuss the management for nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) during Tuesday’s AASLD Clinical Symposium Identification and Management of Patients with NAFLD/NASH.
Six cutting-edge abstracts will be presented during Sunday afternoon’s AASLD Plenary Session, which will be moderated by AASLD President Anna S. Lok, MD, FAASLD, and AASLD Secretary Kimberly A. Brown, MD, FAASLD.
In the last decade, considerable time and resources have been devoted to hepatitis C research, leading to significant treatment breakthroughs.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury (DILI) Network to collect and analyze cases of severe liver injury caused by prescription drugs, herbal products and supplements.
“Christina Lindenmeyer, MD
Gastroenterology and Hepatology Fellow at Cleveland Clinic, OH; Member of the AASLD Membership and Mentorship Committee, Social Media and Technology Committee and Young Investigator Task Force”
Expert will discuss strategies to optimize treatment response for challenging hep C patients who fail therapy
Current treatments for hepatitis C virus (HCV) are quite effective, with a cure rate inching toward 100 percent. However, there are certain subpopulations that fail direct-acting antiviral (DAA) therapy and others who have yet to be diagnosed — up to 50 percent of people with the virus, according to some estimates.